613 lines
38 KiB
Text
613 lines
38 KiB
Text
|
||
<!DOCTYPE html>
|
||
<html lang="en" dir="ltr">
|
||
<head>
|
||
<meta charset="utf-8" />
|
||
<meta name="description" content="Researchers have found that an antiviral drug, often used to suppress genital herpes, also decreases the recurrence of herpes of the eye. A paper detailing these findings is published in the July 30, 1998 issue of The New England Journal of Medicine" />
|
||
<meta name="keywords" content="Infectious Disease" />
|
||
<meta name="google" content="vityevxlt8UuVFWvgz9_YwmJ5F0Nby_B3t54LLh-3Zw,lACaj571Gx_VdLF3HKSKUf1Wxx0H_bWxO3BYDZ_C1uw" />
|
||
<meta name="google-site-verification" content="vityevxlt8UuVFWvgz9_YwmJ5F0Nby_B3t54LLh-3Zw" />
|
||
<meta name="google-site-verification" content="lACaj571Gx_VdLF3HKSKUf1Wxx0H_bWxO3BYDZ_C1uw" />
|
||
<meta name="google-site-verification" content="UDfyeEAWNX_rJUHwog9j1kziEnByGwhkSJGLJclUWDA" />
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
|
||
<script type="application/ld+json">{
|
||
"@context": "https://schema.org",
|
||
"@graph": [
|
||
{
|
||
"@type": "NewsArticle",
|
||
"@id": "https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye",
|
||
"name": "Antiviral Drug Sharply Reduces Return of Herpes of the Eye",
|
||
"headline": "Antiviral Drug Sharply Reduces Return of Herpes of the Eye",
|
||
"image": {
|
||
"@type": "ImageObject",
|
||
"representativeOfPage": "False",
|
||
"url": "https://www.nei.nih.gov/sites/default/files/styles/medium/public/2019-04/NEI_Logo.jpg?itok=QPXvn3Ph",
|
||
"width": "730",
|
||
"height": "670"
|
||
},
|
||
"datePublished": "1998-07-29T17:42:25-0400",
|
||
"dateModified": "2025-01-29T14:34:07-0500",
|
||
"author": {
|
||
"@type": "GovernmentOrganization",
|
||
"@id": "https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye",
|
||
"name": "National Eye Institute",
|
||
"url": "https://www.nei.nih.gov"
|
||
},
|
||
"publisher": {
|
||
"@type": "GovernmentOrganization",
|
||
"@id": "https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye",
|
||
"name": "National Eye Institute",
|
||
"url": "https://www.nei.nih.gov"
|
||
}
|
||
},
|
||
{
|
||
"@type": "WebPage",
|
||
"@id": "https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye",
|
||
"breadcrumb": {
|
||
"@type": "BreadcrumbList",
|
||
"itemListElement": [
|
||
{
|
||
"@type": "ListItem",
|
||
"position": 1,
|
||
"name": "Home",
|
||
"item": "https://www.nei.nih.gov/"
|
||
},
|
||
{
|
||
"@type": "ListItem",
|
||
"position": 2,
|
||
"name": "About NEI",
|
||
"item": "https://www.nei.nih.gov/about"
|
||
},
|
||
{
|
||
"@type": "ListItem",
|
||
"position": 3,
|
||
"name": "News and Events",
|
||
"item": "https://www.nei.nih.gov/about/news-and-events"
|
||
},
|
||
{
|
||
"@type": "ListItem",
|
||
"position": 4,
|
||
"name": "NEI Research News",
|
||
"item": "https://www.nei.nih.gov/about/news-and-events/news"
|
||
},
|
||
{
|
||
"@type": "ListItem",
|
||
"position": 5,
|
||
"name": "Antiviral Drug Sharply Reduces Return of Herpes of the Eye",
|
||
"item": "https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye"
|
||
}
|
||
]
|
||
},
|
||
"author": {
|
||
"@type": "GovernmentOrganization",
|
||
"@id": "https://www.nei.nih.gov",
|
||
"name": "National Eye Institute",
|
||
"url": "https://www.nei.nih.gov"
|
||
},
|
||
"publisher": {
|
||
"@type": "GovernmentOrganization",
|
||
"@id": "https://www.nei.nih.gov",
|
||
"name": "National Eye Institute",
|
||
"url": "https://www.nei.nih.gov"
|
||
}
|
||
}
|
||
]
|
||
}</script>
|
||
<link rel="icon" type="image/png" href="/themes/custom/nei/images/favicon.png" />
|
||
<link rel="apple-touch-icon" href="/themes/custom/nei/images/apple-touch-icon.png" />
|
||
<meta name="last-updated" content="Jan 29, 2025, 2:34:07 PM" />
|
||
<link rel="icon" href="/themes/custom/nei/favicon.ico" type="image/vnd.microsoft.icon" />
|
||
<link rel="alternate" hreflang="en" href="https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye" />
|
||
<link rel="canonical" href="https://www.nei.nih.gov/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye" />
|
||
<link rel="shortlink" href="https://www.nei.nih.gov/node/3613" />
|
||
|
||
<title>Antiviral Drug Sharply Reduces Return of Herpes of the Eye | National Eye Institute</title>
|
||
<link rel="preload" href="/themes/custom/nei/fonts/Aleo-Bold.woff2" as="font" type="font/woff2" crossorigin>
|
||
<link rel="preload" href="/themes/custom/nei/fonts/Lato-Regular.woff2" as="font" type="font/woff2" crossorigin>
|
||
<link rel="stylesheet" media="all" href="/sites/default/files/css/css_PGSk_7b88hq2qr_--_38MLvoj1ffr9jv3JhnNJTnKUM.css?delta=0&language=en&theme=nei&include=eJw1ytEKgCAMRuEXsnwk-dMxrOliTqi3j4iuDnycfFCprpbyHK4tDb-FRvwSshrFYvOErNhxBUHnCaYEcbJ_61Qji26Q5ZXa-QH_YCJ9" />
|
||
<link rel="stylesheet" media="all" href="/themes/custom/nei/css/style.css?sraguf" />
|
||
|
||
<script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/3613","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","gtag":{"tagId":"","consentMode":false,"otherIds":[],"events":[],"additionalConfigInfo":[]},"suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxdjFsOwjAMBC8U6iNFbmKZgPNQ7BTK6SmgCsrPrndkTbhSTFa7D0OtZq-2Cil8yoWOj5WYYT8c18pC3pCBt_jfE17wfoTZCRYeyORRjPruLmhpIS-b2EvFmArD73CFErDUGeWkoadmekCb5fXVsCN3bGeF2EdDmb5kGqWNWZKeKTpd1SjDjEpuSXRTeOeUaxxCT9WYZ50","theme":"nei","theme_token":null},"ajaxTrustedUrl":{"form_action_p_pvdeGsVG5zNF_XLGPTvYSKCf43t8qZYSwcfZl2uzM":true},"gtm":{"tagId":null,"settings":{"data_layer":"dataLayer","include_classes":false,"allowlist_classes":"google\nnonGooglePixels\nnonGoogleScripts\nnonGoogleIframes","blocklist_classes":"customScripts\ncustomPixels","include_environment":false,"environment_id":"","environment_token":""},"tagIds":["GTM-TLVNS7W"]},"user":{"uid":0,"permissionsHash":"c48594e108b5c1c2bea409821b71477d5bc2724c8cae6d31f1d985af0daab85c"}}</script>
|
||
<script src="/sites/default/files/js/js_WgzMsgqb-MiW-Z2aLffGQHepZwX2hWrEHSrb46WqZrk.js?scope=header&delta=0&language=en&theme=nei&include=eJxdjEEOgCAMBD-E9kmkYrOpqdQAMerr5eBBvUx29jCp8HUKQOkZAe4wiY1B6Pj7yAsf33MNmZvuEq0nojnPmkFvCVmUYD6xDTUV3Vq9ATUbLxk"></script>
|
||
<script src="https://script.crazyegg.com/pages/scripts/0117/6571.js" async></script>
|
||
<script src="/modules/contrib/google_tag/js/gtag.js?sraguf"></script>
|
||
<script src="/modules/contrib/google_tag/js/gtm.js?sraguf"></script>
|
||
|
||
</head>
|
||
<body class="t-news_item t-node__3613 path-about-news-and-events-news-antiviral-drug-sharply-reduces-return-herpes-eye">
|
||
<a href="#main-content" class="u-skip-link">
|
||
Skip to content
|
||
</a>
|
||
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-TLVNS7W"
|
||
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
|
||
|
||
<div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
|
||
|
||
<div id="u-page-outer" class="u-outer">
|
||
<div class="views-element-container site-notice-block" id="block-views-block-site-notices-block-1">
|
||
|
||
|
||
|
||
|
||
|
||
<div>
|
||
<div class="js-view-dom-id-72cc1632abbd95ff8cb03c6ae8981e019774d612a073afaf82d31d2acd4b8a84 site-notices">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
<img src="/themes/custom/nei/images/NEI-logo-tagline.svg" alt="" width="200" height="48" class="u-print-only">
|
||
<div class="r-global-header">
|
||
<div id="r-header-outer" class="r-header">
|
||
|
||
<div class="r-header-inner">
|
||
|
||
<div id="block-nei-branding" class="o-block--logo" role="banner">
|
||
|
||
|
||
|
||
|
||
|
||
<div class="o-logo">
|
||
<a href="/" class="o-logo__link" title="Home" rel="home"><span class="o-logo__text">National Eye Institute</span> <span class="o-logo__tagline">Research Today… Vision Tomorrow</span></a>
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
<div id="block-neimenubutton-2">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<div class="o-menu-toggle"><button class="o-menu-toggle__btn" id="menu-toggle__btn" aria-controls="block-mainnavigation" aria-expanded="true">Menu</button></div>
|
||
|
||
|
||
|
||
|
||
</div>
|
||
<div class="language-switcher-language-url has-no-translation" id="block-languageswitcher" role="navigation" aria-label="Language switcher">
|
||
|
||
|
||
<ul class="links">
|
||
<li class="is-active">
|
||
<a href="/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye" class="language-link is-active" lang="en" data-drupal-link-system-path="node/3613" aria-current="page">English</a>
|
||
</li>
|
||
<li>
|
||
<a href="/espanol/node/3613" class="language-link is-active" lang="es" data-drupal-link-system-path="node/3613" aria-current="page"> Español</a>
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
</div>
|
||
<div class="search-global c-search--global" data-drupal-selector="search-global" id="block-globalsearchform" role="search">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<form action="/about/news-and-events/news/antiviral-drug-sharply-reduces-return-herpes-eye" method="post" id="search-global" accept-charset="UTF-8">
|
||
<div class="c-form__inner">
|
||
<div class="js-form-item form-item js-form-type-textfield form-item-global-terms js-form-item-global-terms">
|
||
<label for="edit-global-terms">Search the site</label>
|
||
<input data-drupal-selector="edit-global-terms" type="text" id="edit-global-terms" name="global-terms" value="" size="30" maxlength="128" placeholder="Search the site" class="form-text" />
|
||
|
||
</div>
|
||
<input data-drupal-selector="form-c3gzake9n9rplbihgp29orsdt-j2b7izhlfruozgad8" type="hidden" name="form_build_id" value="form-c3gZAke9n9RpLbihGP29OrSDT-j2B7IzhlfruOzgaD8" />
|
||
<input data-drupal-selector="edit-search-global" type="hidden" name="form_id" value="search_global" />
|
||
<div data-drupal-selector="edit-global-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-global-actions"><input data-drupal-selector="edit-global-submit" type="submit" id="edit-global-submit" name="op" value="Search" class="button js-form-submit form-submit" />
|
||
</div>
|
||
|
||
</div>
|
||
</form>
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div class="r-menu-primary">
|
||
<nav aria-label="Main navigation" id="block-mainnavigation" class="o-menu-main__outer">
|
||
|
||
<ul class="o-menu o-menu-main"> <li class="o-menu-main__item o-menu-main__item--expanded o-menu-main__item--no-js"> <a href="/learn-about-eye-health" class="o-menu-main__link" data-drupal-link-system-path="node/39">Learn About Eye Health</a>
|
||
<ul class="o-menu o-menu-main__submenu"> <li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/learn-about-eye-health/healthy-vision" class="o-menu-main__link" data-drupal-link-system-path="node/788">Healthy Vision</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/learn-about-eye-health/eye-conditions-and-diseases" class="o-menu-main__link" data-drupal-link-system-path="learn-about-eye-health/eye-conditions-and-diseases">Eye Conditions and Diseases</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/learn-about-eye-health/eye-health-data-and-statistics" class="o-menu-main__link" data-drupal-link-system-path="node/825">Eye Health Data and Statistics</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/learn-about-eye-health/campaigns" class="o-menu-main__link" data-drupal-link-system-path="node/3859">Campaigns</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/learn-about-eye-health/vision-rehabilitation" class="o-menu-main__link" data-drupal-link-system-path="node/3865">Vision Rehabilitation</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/learn-about-eye-health/nei-for-kids" class="o-menu-main__link" data-drupal-link-system-path="node/162">NEI for Kids</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/learn-about-eye-health/outreach-resources" class="o-menu-main__link" data-drupal-link-system-path="node/125">Outreach Resources</a>
|
||
</li>
|
||
</ul>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--expanded o-menu-main__item--no-js"> <a href="/grants-and-training" class="o-menu-main__link" data-drupal-link-system-path="node/143">Grants and Training</a>
|
||
<ul class="o-menu-main__submenu o-menu"> <li class="o-menu-main__item"> <a href="/grants-and-training/how-apply" class="o-menu-main__link" data-drupal-link-system-path="node/145">How to Apply</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/funding-opportunities" class="o-menu-main__link" data-drupal-link-system-path="node/144">Funding Opportunities</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/training-nei" class="o-menu-main__link" data-drupal-link-system-path="node/146">Training at NEI</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/funding-training-and-career-development" class="o-menu-main__link" data-drupal-link-system-path="node/152">Funding for Training and Career Development</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/policies-and-procedures" class="o-menu-main__link" data-drupal-link-system-path="node/149">Policies and Procedures</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/grants-and-training/Prior-Approval-Requests" class="o-menu-main__link" data-drupal-link-system-path="node/3918">Prior Approval Requests</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/resources-researchers" class="o-menu-main__link" data-drupal-link-system-path="node/150">Resources for Researchers</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/grants-and-training/contact-grants-and-funding-staff" class="o-menu-main__link" data-drupal-link-system-path="node/151">Contact Grants and Funding Staff</a>
|
||
</li>
|
||
</ul>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--expanded o-menu-main__item--no-js"> <a href="/research" class="o-menu-main__link" data-drupal-link-system-path="node/41">Research at NEI</a>
|
||
<ul class="o-menu-main__submenu o-menu"> <li class="o-menu-main__item"> <a href="/about/news-and-events/news" title="Research News" class="o-menu-main__link" data-drupal-link-system-path="about/news-and-events/news">Research News</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/research/clinical-trials" class="o-menu-main__link" data-drupal-link-system-path="node/132">Clinical Trials</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/research/research-labs-and-branches" class="o-menu-main__link" data-drupal-link-system-path="node/270">Research Labs and Branches</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/research/jobs-and-training-opportunities-nei" class="o-menu-main__link" data-drupal-link-system-path="node/564">Jobs and Training Opportunities at NEI</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/research/seminars" class="o-menu-main__link" data-drupal-link-system-path="node/4048">NEI Research Seminars</a>
|
||
</li>
|
||
</ul>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--expanded o-menu-main__item--no-js"> <a href="/about" class="o-menu-main__link" data-drupal-link-system-path="node/275">About NEI</a>
|
||
<ul class="o-menu-main__submenu o-menu"> <li class="o-menu-main__item"> <a href="/about/strategic-planning" class="o-menu-main__link" data-drupal-link-system-path="node/2857">Strategic Planning</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/news-and-events" class="o-menu-main__link" data-drupal-link-system-path="node/131">News and Events</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/goals-and-accomplishments" class="o-menu-main__link" data-drupal-link-system-path="node/281">Goals and Accomplishments</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/nei-history" class="o-menu-main__link" data-drupal-link-system-path="node/282">NEI History</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/nei-leadership" class="o-menu-main__link" data-drupal-link-system-path="node/415">NEI Leadership</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/budget-and-congress" class="o-menu-main__link" data-drupal-link-system-path="node/395">Budget and Congress</a>
|
||
</li>
|
||
<li class="o-menu-main__item o-menu-main__item--collapsed"> <a href="/about/advisory-committees" class="o-menu-main__link" data-drupal-link-system-path="node/285">Advisory Committees</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/learn-about-eye-health/outreach-resources/national-eye-health-education-program" title="National Eye Health Education Program" class="o-menu-main__link" data-drupal-link-system-path="node/265">National Eye Health Education Program</a>
|
||
</li>
|
||
<li class="o-menu-main__item"> <a href="/about/donate-nei" class="o-menu-main__link" data-drupal-link-system-path="node/286">Donate to NEI</a>
|
||
</li>
|
||
</ul>
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
</nav>
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<div class="o-overlay" aria-hidden="true"></div>
|
||
|
||
<div class="r-breadcrumb">
|
||
|
||
<div id="block-nei-breadcrumbs">
|
||
|
||
|
||
|
||
|
||
|
||
<nav aria-label="Breadcrumb">
|
||
<ol class="c-breadcrumb">
|
||
<li>
|
||
<a href="/">Home</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about">About NEI</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about/news-and-events">News and Events</a>
|
||
</li>
|
||
<li>
|
||
<a href="/about/news-and-events/news">NEI Research News</a>
|
||
</li>
|
||
<li>
|
||
Antiviral Drug Sharply Reduces Return of Herpes of the Eye
|
||
</li>
|
||
</ol>
|
||
</nav>
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<div class="r-page-header">
|
||
<div class="o-page-header">
|
||
|
||
<div id="block-nei-page-title">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<h1>
|
||
<span>Antiviral Drug Sharply Reduces Return of Herpes of the Eye</span>
|
||
</h1>
|
||
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<div class="r-highlighted">
|
||
<div data-drupal-messages-fallback class="hidden"></div>
|
||
|
||
|
||
</div>
|
||
|
||
<div class="r-help">
|
||
|
||
</div>
|
||
<main id="main-content" class="r-main">
|
||
<div class="r-pre-content">
|
||
|
||
</div>
|
||
|
||
<div class="r-splitter">
|
||
<div class="r-content">
|
||
|
||
<div id="block-nei-content">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<article data-history-node-id="3613">
|
||
|
||
|
||
|
||
<div>
|
||
|
||
<div class="c-item__date">
|
||
July 29, 1998
|
||
</div>
|
||
|
||
|
||
|
||
|
||
<div class="c-item__tag c-item__tag--topic">
|
||
<a href="/about/news-and-events/news?topic=350" hreflang="en">Infectious Disease</a>
|
||
</div>
|
||
|
||
|
||
|
||
|
||
|
||
<div class="c-item__tag c-item__tag--research-type">
|
||
<a href="/about/news-and-events/news?research=6" hreflang="en">Clinical Research</a>
|
||
</div>
|
||
|
||
|
||
|
||
|
||
|
||
<div class="c-item__tag c-item__tag--source">
|
||
<a href="/about/news-and-events/news?source=123" hreflang="en">NEI</a>
|
||
</div>
|
||
|
||
|
||
|
||
|
||
|
||
<div class="o-news__content">
|
||
<div class="c-text">
|
||
|
||
|
||
|
||
|
||
<p>Researchers have found that an antiviral drug, often used to suppress genital herpes, also decreases the recurrence of herpes of the eye. A paper detailing these findings is published in the July 30, 1998 issue of <em>The New England Journal of Medicine</em>.</p><p>Scientists found that the drug acyclovir, taken by mouth, reduced by 41 percent the probability that any form of herpes of the eye would return in patients who had the infection in the previous year. Importantly, researchers noted a 50 percent reduction in the rate of return of the more severe form of the disease stromal keratitis among patients who had this infection during the past year. Stromal keratitis causes scarring of the cornea, which can lead to loss of vision and possibly blindness. Recurring episodes of stromal keratitis can often result in the need for a corneal transplant.</p><p>“This drug is the first treatment that helps prevent herpes of the eye from returning,” said Dr. Carl Kupfer, director of the National Eye Institute (NEI), part of the Federal government’s National Institutes of Health (NIH) and the agency that supported the clinical trial. “The results of this study should change medical practice.”</p><p>Herpes of the eye, or ocular herpes, is caused by the herpes simplex virus. This infection can produce a painful sore on the eyelid or surface of the eye and cause inflammation of the cornea, the transparent tissue that covers the front of the eye. The less severe forms of ocular herpes include blepharitis, conjunctivitis, and epithelial keratitis. The more severe form of ocular herpes is stromal keratitis, which causes the body’s immune system to attack and destroy an inner layer of the cornea. Stromal keratitis is more difficult to treat than less severe ocular herpes infections.</p><p>An estimated 400,000 Americans have had some form of ocular herpes. Previous studies show that once people develop ocular herpes, they have up to a 50 percent chance of having a recurrence. This second flare-up could come weeks or even years after the initial occurrence. Each year, nearly 50,000 new and recurring cases are diagnosed in the United States, with the more serious stromal keratitis accounting for about 25 percent.</p><p>The clinical trial called the Acyclovir Prevention Trial (APT) followed 703 patients who had herpes of the eye during the preceding year, but did not currently have an active case of the disease. Of this number, 357 received acyclovir by mouth, and 346 received a placebo. Researchers discovered that the probability of a recurrence of any form of ocular herpes during the treatment period was significantly lower in the acyclovir group (19 percent) than in the placebo group (32 percent). This represents a reduction by 41 percent between the two groups.</p><p>Among the 703 patients, researchers examined 337 patients with a prior history of the more serious stromal keratitis. Acyclovir reduced the rate of recurrences of stromal keratitis from 28 percent to 14 percent, a difference of 50 percent between the two groups. The study medication caused no serious side effects.</p><p>“The study clearly shows that acyclovir therapy can benefit people with all forms of ocular herpes,” said Dr. Kirk Wilhelmus, professor in the Department of Ophthalmology at the Baylor College of Medicine and chairman of the APT clinical trial. “Ocular herpes can be painful, chronic, and disabling. This new treatment will improve people’s quality of life. Those who have had the more serious stromal keratitis will benefit the most.”</p><p>Dr. Wilhelmus noted that not all patients had the same benefit from taking acyclovir. “Patients should consult with their eye care professionals to see if prolonged use of acyclovir is right for them,” he said.</p><p>Researchers also found that oral acyclovir reduced the risk of herpes infections in other parts of the body, particularly the mouth and face, by 43 percent. During the 12-month treatment period, 20 percent of patients in the group receiving acyclovir had at least one herpes infection affecting the mouth or face, as compared with 35 percent of patients in the placebo group.</p><p>Once treatment stopped, the rate of ocular herpes or herpes affecting the mouth and face did not increase, according to Dr. Wilhelmus. “During the six months after treatment ended, the percentages of herpes recurrences affecting the eye or the mouth and face was the same in both the treatment and placebo groups,” he said.</p><p>The Acyclovir Prevention Trial is part of a larger study called the Herpetic Eye Disease Study that is supported through cooperative agreements with the NEI. The APT was conducted at 74 university and community-based clinical sites nationwide, reporting to eight regional centers. A list of the regional centers is attached.</p><p><em>The National Eye Institute, part of the National Institutes of Health, is the Federal government’s lead agency for vision research, and supports between 70 to 80 percent of basic and applied vision research in the United States.</em></p><p>###</p><h2>Background</h2><h2>The Acyclovir Prevention Trial</h2><h3>Ocular Herpes</h3><p>Like other herpetic infections, herpes of the eye remains a controllable, but incurable, problem. In one large, unrelated study, researchers found that recurrence rate of ocular herpes was 10 percent within one year, 23 percent within two years, and 63 percent within 20 years. Some factors believed to be associated with recurrence include fever, stress, sunlight, and eye injury.</p><p>The less severe forms of ocular herpes include epithelial keratitis, conjunctivitis, and blepharitis. The more severe form of ocular herpes stromal keratitis can lead to corneal scarring and can be associated with secondary glaucoma and cataract. Standard treatment with antiviral eyedrops or ointment helps to stop the herpes virus from multiplying. However, until the APT, there was still no known effective method for reducing the frequency of ocular herpes recurrence.</p><h3>The APT Protocol</h3><p>The Acyclovir Prevention Trial (APT) is a multicenter randomized clinical trial designed to determine if the antiviral drug acyclovir, given orally, would prevent herpes simplex virus infection from recurring in the eyes of patients who had the infection in the past.</p><p>To be eligible for participation, patients must have experienced a form of ocular herpes in one or both eyes during the preceding year. This infection had to be inactive and untreated for at least the previous 30 days before enrollment. About 29 percent of the enrolled patients had experienced one previous episode of ocular herpes; 71 percent experienced multiple previous recurrences. The most common types of prior ocular herpes were epithelial keratitis (47 percent), stromal keratitis (16 percent), and both epithelial keratitis and stromal keratitis (32 percent). About 49 percent of patients had a history of fever blisters or other previous symptoms of herpes of the mouth and/or face.</p><p>Of the 703 patients, 357 were randomly assigned to the acyclovir group, and 346 to the placebo group. All patients were followed for all forms of ocular and nonocular recurrences during a 12-month treatment period, followed by a six-month observation period. The acyclovir group received oral acyclovir 400 mg twice daily for 12 months. The other group received placebo capsules that were identical in appearance and taste to the acyclovir capsules. Study medication (acyclovir or placebo) was continued for the full 12 months regardless of whether a recurrence occurred.</p><p>Herpes recurrences were classified as either superficial ocular infections (blepharitis, conjunctivitis, and/or epithelial keratitis); stromal keratitis; or iritis. When patients had a recurrence of ocular herpes, they were treated with standard topical medication, but continued to receive the oral acyclovir or placebo for the entire 365-day period.</p><p>Only four percent of patients in the acyclovir group and five percent in the placebo group stopped treatment because of side effects. One-half of these side effects were due to gastrointestinal upset; some patients may have had intolerance to the lactose contained in the study capsules (Treatment medication that does not contain lactose is now available).</p><p>Glaxo Wellcome supplied to APT investigators over a half million free capsules of its brand name acyclovir, called Zovirax®.</p><h3>Secondary Findings</h3><p>In addition to the main findings, doctors also noted that:</p><ul><li>During the 12 months of treatment, oral acyclovir reduced the incidence of epithelial keratitis from 11 percent to nine percent, and the incidence of stromal keratitis from 13 percent to eight percent.</li><li>During the 12-month treatment period, four percent of patients in the acyclovir group and nine percent in the placebo group had more than one recurrence.</li></ul><h2>Herpetic Eye Disease Study Centers</h2><p><strong>California</strong><br>Chandler R. Dawson, M.D<br>Francis I. Proctor Foundation<br>University of California, San Francisco<br>San Francisco, CA</p><p><strong>Georgia</strong><br>R. Doyle Stulting, M.D., Ph.D.<br>Emory Eye Center<br>Atlanta, GA</p><p><strong>Illinois</strong><br>Joel Sugar, M.D.<br>Eye Center<br>University of Illinois, Chicago<br>Chicago, IL</p><p><strong>Louisiana</strong><br>Bruce A. Barron, M.D.<br>Louisiana State University Eye Center<br>New Orleans, LA</p><p><strong>New York</strong><br>Penny A. Asbell, M.D.<br>Department of Ophthalmology<br>The Mount Sinai Medical Center<br>New York, NY</p><p><strong>Pennsylvania</strong><br>Elisabeth J. Cohen, M.D.<br>Wills Eye Hospital, Cornea Clinic<br>Philadelphia, PA</p><p><strong>Texas</strong><br>Kirk R. Wilhelmus, M.D.<br>Cullen Eye Institute<br>Baylor College of Medicine<br>Houston, TX</p><p><strong>Wisconsin</strong><br>Robert A. Hyndiuk, M.D.<br>The Eye Institute<br>Medical College of Wisconsin<br>Milwaukee, WI</p><p> </p><h3>Resource Centers</h3><p><strong>Chairman’s Office</strong></p><p>Chandler R. Dawson, M.D.<br>Francis I. Proctor Foundation<br>University of California, San Francisco<br>153 Parnassus Avenue, Room 5347<br>San Francisco, CA 94143-0412<br>Telephone: (415) 476-2658</p><p><strong>Coordinating Center</strong></p><p>Roy W. Beck, M.D., Ph.D.<br>Pamlea S. Moke, M.S.P.H.<br>Jaeb Center for Health Research, Inc.<br>3010 E. 138th Avenue, Suite 9<br>Tampa, FL 33613<br>Telephone: (813) 975-8690</p><h3>NEI Representative</h3><p>Natalie Kurinij, Ph.D.<br>National Eye Institute<br>National Institutes of Health<br>Executive Plaza South, Suite 350<br>6120 Executive Boulevard, MSC 7164<br>Bethesda, MD 20892-7164<br>Telephone: (301) 496-5983</p><p>###</p><h3>Citations</h3><ul><li>Acyclovir for The Prevention of Recurrent Herpes Simplex Virus Eye Disease. Herpetic Eye Disease Study Group. <em>N Engl J Med</em>. 1998 Jul 30. <a href="https://pubmed.ncbi.nlm.nih.gov/9696640/">PubMed</a></li></ul>
|
||
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
</article>
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
<aside class="r-sidebar" role="complementary">
|
||
|
||
<div class="views-element-container" id="block-views-block-nei-sidebar-block-1">
|
||
|
||
|
||
|
||
|
||
|
||
<div>
|
||
<div class="js-view-dom-id-dd4f601920c0af889f5e725de0456b2dd452f62dba2c4b7d06ebd747b19671f2 nei-sidebar">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</aside>
|
||
</div>
|
||
</main>
|
||
|
||
<div class="r-footer">
|
||
<footer class="o-footer" role="contentinfo">
|
||
|
||
<div id="block-footer-2">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<div class="o-footer__row">
|
||
<div class="o-footer__group o-footer__group--logo"><a class="o-logo__link" href="/" rel="home" title="Home"><span class="o-logo__text">National Eye Institute</span></a>
|
||
<ul class="o-menu-social">
|
||
<li class="o-menu-social__item"><a class="o-menu-social__link o-menu-social__link--facebook outlink-ignore" href="https://www.facebook.com/NationalEyeInstitute">Facebook</a></li>
|
||
<li class="o-menu-social__item"><a class="o-menu-social__link o-menu-social__link--twitter outlink-ignore" href="https://twitter.com/NatEyeInstitute">Twitter</a></li>
|
||
<li class="o-menu-social__item"><a class="o-menu-social__link o-menu-social__link--linkedin outlink-ignore" href="https://www.linkedin.com/company/national-eye-institute-nei">LinkedIn</a></li>
|
||
<li class="o-menu-social__item"><a class="o-menu-social__link o-menu-social__link--youtube outlink-ignore" href="https://www.youtube.com/user/neinih">YouTube</a></li>
|
||
</ul>
|
||
|
||
<p> </p>
|
||
</div>
|
||
|
||
<div class="o-footer__group o-footer__group--contact">
|
||
<h2 class="o-footer__title">Contact NEI</h2>
|
||
|
||
<ul class="o-menu-footer">
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/contact-us/">Contact Us</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://www.nih.gov/about-nih/visitor-information">Visit NIH</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://list.nih.gov/cgi-bin/wa.exe?SUBED1=insidenei&A=1">Get Email Updates from NEI</a></li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="o-footer__group o-footer__group--policies">
|
||
<h2 class="o-footer__title">Policies</h2>
|
||
|
||
<ul class="o-menu-footer">
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/accessibility-information">Accessibility</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://www.nih.gov/nondiscrimination-notice-language-assistance-services">Information in Other Languages</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/nei-website-privacy-policy">Privacy</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/freedom-information-act">Freedom of Information Act (FOIA)</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/disclaimers">Disclaimers</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="/web-policies ">Web Policies</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html ">Vulnerability Disclosure</a></li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="o-footer__group o-footer__group--employees">
|
||
<h2 class="o-footer__title">For NEI Employees</h2>
|
||
|
||
<ul class="o-menu-footer">
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://intranet.nei.nih.gov">Intranet</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://intranet.nei.nih.gov/hr/Pages/emergency.aspx">Emergency Information</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://ned.nih.gov/search/search.aspx">NIH Staff Directory</a></li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="o-footer__row">
|
||
<div class="o-footer__full o-footer__full--parent">
|
||
<ul class="o-menu-footer o-menu-footer--swing">
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://www.nih.gov/">NIH.gov</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://hhs.gov/">HHS.gov</a></li>
|
||
<li class="o-menu-footer__item"><a class="o-menu-footer__link" href="https://usa.gov/">USA.gov</a></li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</footer>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<div class="c-lb-wrapper" id="lb-wrapper" aria-hidden="true">
|
||
<div class="c-lb-overlay" tabindex="-1"></div>
|
||
<div role="dialog" class="c-lb" id="lb">
|
||
<div class="c-lb-header">
|
||
<button class="c-lb-close-btn"><span class="c-lb-close-btn-text">Close</span><span class="c-lb-close-btn-text times" aria-hidden="true">×</span></button>
|
||
</div>
|
||
<figure class="c-lb-figure">
|
||
<figcaption class="c-lb-caption"></figcaption>
|
||
</figure>
|
||
</div>
|
||
</div>
|
||
|
||
<script src="/sites/default/files/js/js_agazM-qm5cOcplNZo9kNIWFtUrwt0V1xgAKtLyM44Us.js?scope=footer&delta=0&language=en&theme=nei&include=eJxdjEEOgCAMBD-E9kmkYrOpqdQAMerr5eBBvUx29jCp8HUKQOkZAe4wiY1B6Pj7yAsf33MNmZvuEq0nojnPmkFvCVmUYD6xDTUV3Vq9ATUbLxk"></script>
|
||
<script src="/themes/custom/nei/js/scripts.js?sraguf"></script>
|
||
|
||
</body>
|
||
</html>
|